IL319684A - נוגדנים חד-שבטיים אנטי- ccr8והשימוש הרפואי בהם - Google Patents
נוגדנים חד-שבטיים אנטי- ccr8והשימוש הרפואי בהםInfo
- Publication number
- IL319684A IL319684A IL319684A IL31968425A IL319684A IL 319684 A IL319684 A IL 319684A IL 319684 A IL319684 A IL 319684A IL 31968425 A IL31968425 A IL 31968425A IL 319684 A IL319684 A IL 319684A
- Authority
- IL
- Israel
- Prior art keywords
- ccr8
- monoclonal antibodies
- therapeutic use
- therapeutic
- monoclonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22306389 | 2022-09-21 | ||
| PCT/EP2023/076155 WO2024062076A1 (en) | 2022-09-21 | 2023-09-21 | Anti-ccr8 monoclonal antibodies and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319684A true IL319684A (he) | 2025-05-01 |
Family
ID=95482473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319684A IL319684A (he) | 2022-09-21 | 2023-09-21 | נוגדנים חד-שבטיים אנטי- ccr8והשימוש הרפואי בהם |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4590703A1 (he) |
| JP (1) | JP2025531391A (he) |
| KR (1) | KR20250111755A (he) |
| CN (1) | CN120476141A (he) |
| AU (1) | AU2023345469A1 (he) |
| CA (1) | CA3268049A1 (he) |
| IL (1) | IL319684A (he) |
| MX (1) | MX2025003315A (he) |
-
2023
- 2023-09-21 JP JP2025517338A patent/JP2025531391A/ja active Pending
- 2023-09-21 CN CN202380080110.0A patent/CN120476141A/zh active Pending
- 2023-09-21 IL IL319684A patent/IL319684A/he unknown
- 2023-09-21 AU AU2023345469A patent/AU2023345469A1/en active Pending
- 2023-09-21 KR KR1020257012889A patent/KR20250111755A/ko active Pending
- 2023-09-21 CA CA3268049A patent/CA3268049A1/en active Pending
- 2023-09-21 EP EP23776068.1A patent/EP4590703A1/en active Pending
-
2025
- 2025-03-20 MX MX2025003315A patent/MX2025003315A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025531391A (ja) | 2025-09-19 |
| CN120476141A (zh) | 2025-08-12 |
| MX2025003315A (es) | 2025-06-02 |
| KR20250111755A (ko) | 2025-07-22 |
| CA3268049A1 (en) | 2024-03-28 |
| AU2023345469A1 (en) | 2025-05-01 |
| EP4590703A1 (en) | 2025-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL319931A (he) | נוגדנים אנטי- cd122 ושימושים בהם | |
| IL289488A (he) | נוגדנים חד שבטיים הקושרים egfrviii ושימושם | |
| GB202012331D0 (en) | Therapeutic antibodies | |
| IL315438A (he) | נוגדנים אנטי-cd3 חדשים ושימושים בהם | |
| EP4413044A4 (en) | ANTI-CD3 MONOCLONAL ANTIBODIES AND THERAPEUTIC CONSTRUCTS | |
| IL308361A (he) | נוגדנים בעלי ספציפיות כפולה ושימושיהם | |
| IL292599A (he) | נוגדנים tmem219 ושימושים רפואיים בהם | |
| IL325570A (he) | נוגדן כנגד cd3 ושימוש בו | |
| IL317849A (he) | נוגדנים חד-שבטיים אנטי- slc34a2ושימושים בהם | |
| IL314622A (he) | נוגדנים מואנשים כנגד Nectin-2 ותרופות מצומדות שלהם | |
| IL320972A (he) | נוגדנים אנטי-tfr1 ושימושים בהם | |
| IL319684A (he) | נוגדנים חד-שבטיים אנטי- ccr8והשימוש הרפואי בהם | |
| IL319678A (he) | נוגדנים חד-שבטיים אנטי- ccr8 והשימוש הרפואי בהם | |
| EP4125946A4 (en) | MONOCLONAL ANTIBODIES TARGETING HSP70 AND THEIR THERAPEUTIC USES | |
| IL308014A (he) | נוגדנים אנטי-גלקטין-9 ושימושים טיפוליים בהם | |
| HK40126953A (en) | Anti-ccr8 monoclonal antibodies and their therapeutic use | |
| EP4314054A4 (en) | SINGLE-DOMAIN ANTI-EGFR ANTIBODIES AND THERAPEUTIC CONSTRUCTS | |
| GB202204813D0 (en) | Human monoclonal antibodies and methods of use thereof | |
| GB202204736D0 (en) | Human monoclonal antibodies and methods of use thereof | |
| IL310551A (he) | נוגדנים חד-שבטיים ספציפיים ל-osmr ושיטות השימוש בהם | |
| EP4486788A4 (en) | ANTI-CD73 ANTIBODIES AND THEIR USES | |
| IL315029A (he) | נוגדנים חד-שבטיים אנטי- il-13ra2ושימושים בהם | |
| IL325073A (he) | נוגדן אנטי-cd200r1 ושימושים בו | |
| GB202311497D0 (en) | Therapeutic antibodies | |
| GB202310818D0 (en) | Therapeutic antibodies |